Q-omics provides the consensus-scored HBZ profile across patient tissues and cancer cell-line models. HBZ expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, HBZ is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, HBZ protein abundance shows 19,628 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, LUAD, and GBM as cancer lineages where HBZ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HBZ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HBZ survival associations across molecular data types. HBZ RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HBZ RNA expression–survival associations across cancer types. High HBZ expression shows unfavorable associations in LUSC, KIRP, MESO and PRAD, but favorable associations in STAD and READ. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for HBZ RNA expression.
This table summarizes HBZ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HBZ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HBZ shows lower tumor expression in LUAD, BRCA, LUSC, UCEC and KICH. The LUAD box plot shows higher HBZ RNA expression in normal versus tumor tissue (log2 FC = −0.166, t-test p < 0.001).
This table shows molecular features associated with HBZ in patient tissues and cancer cell lines. In patient samples, HBZ shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HBZ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
